[{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virpax \u00ae Pharmaceuticals Announces Closing of a $ 40 Million Public Offering of Common Stock","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis India Limited Extends Access to Its Medicines in India by Signing Exclusive Sales and Distribution Agreement With Dr. Reddy\u2019s Laboratories","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Chromocell Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"NEXGEL Advanced Hydrogel Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEXGEL Reports Positive Results from Proof-of-Concept Study for its Diclofenac Hydrogel Pain Treatment","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Rheumatology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000594
Novartis India Limited enters into an exclusive sales and distribution agreement with Dr. Reddy’s Laboratories for a few of its Established Medicines which includes the Voveran® range, the Calcium range and Methergine®.
The partnership grants Chromocell access to concentrate on the clinical advancement of a sublingual formulation of a Diclofenac spray designed for treating acute pain.
DARE-PDM1 (diclofenac) is a vaginal hydrogel which inhibits Cox-1 and Cox-2. It is being evaluated in phase 1 clinical trials for the treatment of primary dysmenorrhea.
Diclofenac hydrogel patches are a nonsteroidal anti-inflammatory drug (NSAIDs) products that are used to treat short-term pain due to minor strains, sprains and bruises.
Virpax intends to use the net proceeds from the offering to fund research and development of the Epoladerm, Probudur, Envelta and AnQlar indications and other development programs in clinical trial.